FDA guidance is:
Advantages of fast track designation include actions to facilitate development and expedite review of the product, such as the possibility for rolling review if FDA determines, after preliminary evaluation of clinical data submitted by a sponsor, that the fast track product may be effective. In addition, such a product could be eligible for priority review if supported by clinical data at the time of marketing application submission.
...
A decision about granting priority review is made within 60 calendar days of receipt of the marketing application or efficacy supplement. If priority review is granted, CBER has a 6 month goal for reviewing the biologics license application (BLA) or efficacy supplement.
https://www.fda.gov/media/120267/download
If approval requires another trial, and the endpoint is pain reduction at 12 months, then it looks like the timeframe for approval may be as soon as ~18 months after the trial completes adequate recruitment and data validation. Perhaps a trial design would include Bayesian analysis with interim reviews to fast-track the recruitment. If such a trial design were used, MSB may have a justification for an 'informative prior' from the excellent results of the previous trial.
https://en.wikipedia.org/wiki/Prior_probability#:~:text=In%20Bayesian%20statistics%2C%20Bayes'%20rule,uncertain%20quantity%20given%20new%20data.
Interesting wording in the statement from SI:
"We look forward to working closely with FDA to efficiently generate the additional data needed to support marketing approval of rexlemestrocel L".
- Forums
- ASX - By Stock
- Ann: FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP
FDA guidance is: Advantages of fast track designation include...
-
-
- There are more pages in this discussion • 94 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 99.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.5¢ | 18069 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 0.990 |
2 | 32880 | 0.985 |
4 | 71034 | 0.980 |
2 | 3059 | 0.975 |
7 | 145890 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.995 | 1132 | 1 |
1.000 | 9500 | 3 |
1.005 | 35000 | 1 |
1.010 | 58113 | 4 |
1.015 | 46100 | 3 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online